Download Image
    
Share
  
Post
Tenecteplase for COVID-19
1 study with 13 patients
Hospital Icon Control
Hospital Icon Tenecteplase Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Tenecteplase studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -25% Mortality -25% Hospitalization 15% RCTs -25% Late -25% Favorstenecteplase Favorscontrol
Tenecteplase is a recombinant tissue plasminogen activator (tPA) and fibrinolytic agent that dissolves blood clots by converting plasminogen to plasmin. Recent:
Poor.
Feb 16
2024
 Poor et al., Cureus, doi:10.7759/cureus.54298 Tenecteplase With Concomitant Anticoagulation for Acute Respiratory Failure in Patients With COVID-19: A Randomized Controlled Trial
25% higher mortality (p=1), 38% lower progression (p=0.59), and 15% shorter hospitalization (p=0.82). RCT 13 hospitalized COVID-19 patients with acute respiratory failure showing no significant difference in mortality or respiratory outcomes with tenecteplase plus heparin versus placebo plus heparin. At 28 days, 63% of tenecteplase patien..